Cadrenal Therapeutics reports Q4 net loss of $3.0M, cash $4.0M; CAD-1005 FDA EOP2 meeting completed

Cadrenal Therapeutics, Inc.

2026-Q1 EPS reported -$1.04

Q4 2025 net loss $3.0M vs $4.2M YoY; R&D expenses $0.7M vs $1.5M; G&A $2.4M vs $2.7M.
Cash and equivalents $4.0M at Dec 31, 2025; evaluating financing and strategic alternatives to support clinical development.
Completed End-of-Phase 2 FDA meeting on March 26, 2026 for CAD-1005; Phase 3 pivotal trial protocol incorporation underway.
Phase 2 HIT study showed >25% absolute reduction in thrombotic events with CAD-1005 vs placebo on standard anticoagulation.
CAD-1005 has Orphan Drug and Fast Track designations from FDA; orphan status from EMA.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cadrenal Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income $3.0 million for the quarter ending December 31, 2025.

Period: the fourth quarter and full year ended December 31, 2025
Net income: $3.0 million for the quarter ending December 31, 2025
Result: reported results

Exact text from the filing

Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release that included financial information for the fiscal year ended December 31, 2025.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

Cadrenal Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-036937

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.